July 9, 2025
| Today’s news and insights for biopharma leaders
The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
|
While Trump indicated drug levies would be set at a “very high” rate, he added that pharma firms would first be given time to bring manufacturing to the U.S.
|
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.
|
Tell your brand’s story. Secure prime ad placements. Generate qualified leads. Reach your marketing goals with BioPharma Dive’s audience of over 360,000 decision makers.
|
News roundup
The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.
|
The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.
|
UPDATED
Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.
|
Improve launch success and optimize investments
|
|
From Our Library
Playbook
Custom content for Premier Research
|
Playbook
Custom content for Medrio
|
Webinar - on demand
Custom content for PPD FSP solutions
|
|